137 related articles for article (PubMed ID: 11269747)
1. Preclinical antitumor activity of two novel taxanes.
Rose WC; Fairchild C; Lee FY
Cancer Chemother Pharmacol; 2001; 47(2):97-105. PubMed ID: 11269747
[TBL] [Abstract][Full Text] [Related]
2. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
Lee FY; Borzilleri R; Fairchild CR; Kim SH; Long BH; Reventos-Suarez C; Vite GD; Rose WC; Kramer RA
Clin Cancer Res; 2001 May; 7(5):1429-37. PubMed ID: 11350914
[TBL] [Abstract][Full Text] [Related]
3. Preclinical oral antitumor activity of BMS-185660, a paclitaxel derivative.
Rose WC; Lee FY; Golik J; Kadow J
Cancer Chemother Pharmacol; 2000; 46(3):246-50. PubMed ID: 11021743
[TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
Sharma A; Straubinger RM; Ojima I; Bernacki RJ
J Pharm Sci; 1995 Dec; 84(12):1400-4. PubMed ID: 8748320
[TBL] [Abstract][Full Text] [Related]
5. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
[TBL] [Abstract][Full Text] [Related]
6. The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells.
Kim JS; Amorino GP; Pyo H; Cao Q; Price JO; Choy H
Int J Radiat Oncol Biol Phys; 2001 Oct; 51(2):525-34. PubMed ID: 11567829
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacology of BMS-275183, an orally active taxane.
Rose WC; Long BH; Fairchild CR; Lee FY; Kadow JF
Clin Cancer Res; 2001 Jul; 7(7):2016-21. PubMed ID: 11448919
[TBL] [Abstract][Full Text] [Related]
8. Preclinical antitumor activity of water-soluble paclitaxel derivatives.
Rose WC; Clark JL; Lee FY; Casazza AM
Cancer Chemother Pharmacol; 1997; 39(6):486-92. PubMed ID: 9118459
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind.
Verweij J; Clavel M; Chevalier B
Ann Oncol; 1994 Jul; 5(6):495-505. PubMed ID: 7918121
[TBL] [Abstract][Full Text] [Related]
10. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
Vredenburg MR; Ojima I; Veith J; Pera P; Kee K; Cabral F; Sharma A; Kanter P; Greco WR; Bernacki RJ
J Natl Cancer Inst; 2001 Aug; 93(16):1234-45. PubMed ID: 11504769
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
12. Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization.
Rose WC; Marathe PH; Jang GR; Monticello TM; Balasubramanian BN; Long B; Fairchild CR; Wall ME; Wani MC
Cancer Chemother Pharmacol; 2006 Jul; 58(1):73-85. PubMed ID: 16228206
[TBL] [Abstract][Full Text] [Related]
13. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor.
Rose WC; Lee FY; Fairchild CR; Lynch M; Monticello T; Kramer RA; Manne V
Cancer Res; 2001 Oct; 61(20):7507-17. PubMed ID: 11606387
[TBL] [Abstract][Full Text] [Related]
14. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
[TBL] [Abstract][Full Text] [Related]
15. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
16. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer.
Boven E; Venema-Gaberscek E; Erkelens CA; Bissery MC; Pinedo HM
Ann Oncol; 1993 Apr; 4(4):321-4. PubMed ID: 8100146
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo.
Tanaka M; Obata T; Sasaki T
Eur J Cancer; 1996 Feb; 32A(2):226-30. PubMed ID: 8664032
[TBL] [Abstract][Full Text] [Related]
19. [Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy].
Fumoleau P; Perrocheau G; Maugard-Louboutin C; Lemevel B
Bull Cancer; 1995 Aug; 82(8):629-36. PubMed ID: 7492819
[TBL] [Abstract][Full Text] [Related]
20. Taxol: the first of the taxanes, an important new class of antitumor agents.
Rowinsky EK; Onetto N; Canetta RM; Arbuck SG
Semin Oncol; 1992 Dec; 19(6):646-62. PubMed ID: 1361079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]